Early Responses to Intravitreal Ranibizumab in Typical Neovascular Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy

Table 2

Changes in the BCVA and CRT from baseline after IVR treatment in tAMD and PCV patients.

	1 month		𝑃 value	3 months		𝑃 value
	Mean	Median; (Interquartile range)		Mean	Median; (Interquartile range)
BCVA
PCV	−0.0086	0.00 (−0.090–0.00)	.38*	−0.011	0.00 (−0.12–0.030)	.55*
tAMD	−0.093	0.00 (−0.17–0.00)	.0084*	−0.19	−0.12 (−0.30–0.00)	.00080*
𝑃 value		.42^†			.0045^†
CRT
PCV	−118	−111 (−166–−32)	<.0001*	−173	−130 (−212–−63)	<.0001*
tAMD	−104	−84 (−147–−57)	<.0001*	−129	−97 (−182–−64)	<.0001*
𝑃 value		.80^†			.58^†

BCVA: best-corrected visual acuity (LogMAR); CRT: central retinal thickness.
*Wilcoxon’s signed-rank test (comparison to baseline).
^†Mann-Whitney 𝑈 test (comparison between PCV and tAMD at the same month).